Database Locked for the Rare Disease Pediatric Study
GCT team is proud of taking part in the achievement of the major milestone for the Phase III clinical trial. The study is being successfully conducted, amidst the present difficult global environment, in pediatric patients suffering from a rare neurological disease. It is a randomized, double-blind, placebo-controlled trial followed by a long-term open label treatment. In January 2020, GCT successfully completed the enrollment of patients in Russia. We have now reached the next milestone – the Database Lock.
Despite all the challenges caused by the pandemic, the GCT team was able to follow each patient closely and ensure they complete all the required assessments, keeping trial participants safe during the treatment stage. This trial required a high level of GCT expertise and involvement, which the team successfully delivered.
“The sponsor of this trial, a US Pharmaceutical company, demonstrated an incredible level of trust in GCT, for which we are extremely grateful. We hope that our professional relationship will continue to grow and develop in the future,” – Dr. Eugene Selivra, GCT CEO.
Updated: September 7, 2020
Permanent link: https://2022.gctrials.com/news/database-locked-for-the-rare-disease-pediatric-study/